Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.

Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S.

Lancet Infect Dis. 2006 Aug;6(8):496-507. Review.

PMID:
16870528
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Treatment of antiretroviral-drug-resistant HIV-1 infection.

Deeks SG.

Lancet. 2003 Dec 13;362(9400):2002-11. Review.

PMID:
14683662
4.

Phenotypic testing predicts virological response in successive protease inhibitor-based regimens.

Pérez-Elías MJ, Lanier R, Muñoz V, Garcia-Arata I, Casado JL, Marti-Belda P, Moreno A, Dronda F, Antela A, Marco S, Moreno S.

AIDS. 2000 Jun 16;14(9):F95-101.

PMID:
10894269
5.

Salvage therapy for patients failing their current antiretroviral regimen.

Albrecht MA.

AIDS Clin Rev. 2000-2001:139-91. Review. No abstract available.

PMID:
10999220
6.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
7.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
8.

The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?

Zaccarelli M, Tozzi V, Perno CF, Antinori A.

Curr HIV Res. 2004 Jul;2(3):283-92. Review.

PMID:
15279592
9.

Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.

Poveda E, Blanco F, García-Gascó P, Alcolea A, Briz V, Soriano V.

AIDS. 2006 Jul 13;20(11):1558-60.

PMID:
16847414
10.
11.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091
12.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
13.

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.

de la Rosa R, Ruíz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M.

J Antimicrob Chemother. 2004 Jan;53(1):95-101. Epub 2003 Dec 4.

PMID:
14657091
14.

Management of HIV infection after triple class failure.

Cossarini F, Spagnuolo V, Gianotti N, Carbone A, Lazzarin A, Castagna A.

New Microbiol. 2013 Jan;36(1):23-39. Epub 2013 Jan 1. Review.

15.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, Harrigan PR.

J Infect Dis. 2004 Jul 15;190(2):285-92. Epub 2004 Jun 11.

PMID:
15216463
16.

Individualized therapy for the treatment-experienced patient.

Walmsley S.

AIDS Read. 2003 Jun;13(6 Suppl):S11-5.

PMID:
12838742
17.

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM.

AIDS. 1999 Apr 16;13(6):F35-43.

PMID:
10397555
18.

Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

Burgos J, Crespo M, Falcó V, Curran A, Imaz A, Domingo P, Podzamczer D, Mateo MG, Van den Eynde E, Villar S, Ribera E.

J Antimicrob Chemother. 2012 Jun;67(6):1453-8. doi: 10.1093/jac/dks057. Epub 2012 Feb 29.

PMID:
22378681
19.

Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.

Salzberger B, Däumer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Sturmer M.

Eur J Med Res. 2007 Mar 26;12(3):93-102.

PMID:
17507306
20.

Supplemental Content

Support Center